Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Obsidian Therapeutics Inc.
Market Cap
$14.55M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.57M
Return on Equity (ROE)
-19.08%
TTM Avg
-28.50%
3Y Avg
-28.27%
5Y Avg
-100.79%
Market Cap
$13.90M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
Market Cap
$15.07M
Return on Equity (ROE)
N/A
TTM Avg
54.00%
3Y Avg
301.36%
5Y Avg
162.15%
Market Cap
$13.97M
Return on Equity (ROE)
-186.95%
TTM Avg
1198.98%
3Y Avg
241.18%
5Y Avg
112.17%
Market Cap
$15.25M
Return on Equity (ROE)
-42.72%
TTM Avg
-65.53%
3Y Avg
-58.02%
5Y Avg
-43.63%
Market Cap
$15.30M
Return on Equity (ROE)
-951.92%
TTM Avg
-161.65%
3Y Avg
-122.41%
5Y Avg
-87.71%
Market Cap
$13.71M
Return on Equity (ROE)
-101.66%
TTM Avg
-140.38%
3Y Avg
-131.64%
5Y Avg
-101.94%
Market Cap
$13.45M
Return on Equity (ROE)
-810.41%
TTM Avg
-174.22%
3Y Avg
-126.94%
5Y Avg
-100.46%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.55M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | -19.08% | -28.50% | -28.27% | -100.79% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.90M | -69.47% | -55.64% | -44.95% | -41.56% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.07M | N/A | 54.00% | 301.36% | 162.15% |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | -186.95% | 1198.98% | 241.18% | 112.17% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.25M | -42.72% | -65.53% | -58.02% | -43.63% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -951.92% | -161.65% | -122.41% | -87.71% |
| IN8bio, Inc. (INAB)vs › | $13.71M | -101.66% | -140.38% | -131.64% | -101.94% |
| Passage Bio, Inc. (PASG)vs › | $13.45M | -810.41% | -174.22% | -126.94% | -100.46% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.81M | -348.81% | -160.92% | -184.71% | -151.29% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
